Stay updated with breaking news from Human Monkeypox Virus. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The University of California San Diego will be one of multiple sites assessing the safety and efficacy of tecovirimat as a potential treatment for human monkeypox.
Massachusetts General Hospital and Brigham and Women's Hospital, the founding members of Mass General Brigham, today announced their participation in STOMP (Study of Tecovirimat for Human Monkeypox Virus), a phase 3, randomized, placebo-controlled, double-blind trial evaluating the safety and efficacy of tecovirimat (TPOXX) for the treatment of human monkeypox.
This article summarizes the ACP/Annals virtual forum held on 11 October 2022.
A new review to be posted in the Virus Research journal aims to provide an overview of the recent advances reported concerning hMPXV virology.
The UCLA Clinical AIDS Research and Education (CARE) Center today announced its participation in STOMP (Study of Tecovirimat for Human Monkeypox Virus), or A5418, a phase 3, randomized, placebo-controlled, double-blind trial evaluating the safety and efficacy of tecovirimat for the treatment of human monkeypox.